Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibition in Preclinical Arthritis
2021-006562-20Phase 2Active
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Aug 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of baricitinib in rheumatoid arthritis (RA), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Development of arthritis (overall). Started Aug 2022; status: active.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-006562-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006562-20.